
Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced <br /> esophageal or gastric cancer.<br />

Your AI-Trained Oncology Knowledge Connection!


Published: February 19th 2018 | Updated: